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Certain guidelines exist to facilitate the decision as to which patients with lower respiratory tract infections require 
antibiotics. The decision as to which antibiotic to use must depend on a detailed knowledge of the disease and the 
patient's condition. Recent recommendations recognize four categories of patients with community-acquired pneumonia 
and adopt somewhat different treatment strategies for each. In industrialized countries, macrolides are regarded as 
either first- or second-choice therapy for community-acquired pneumonias of all grades of severity. 
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Lower respiratory tract infections constitute one of 
the most coinnion indications for antibiotic therapy in 
the adult. One of the reasons is the difficulty in 
distinguishing between disease entities that are life- 
endangering and those that can be successfully managed 
with supportive care only. In addition, many con- 
founding factors, such as age, smoking, the presence of 
obstructive disease, asthma, immunodeficient states and 
epidenliologic considerations, tend to make the clinical 
decision less clear and inore complex [ 1,2]. 
Guidelines have been formed over the years that 
facilitate the decision of which patients to treat with 
antibiotics. They include the following: 
I .  Acute bronchitis does not warrant antibiotic 
therapy as it is caused most frequently by respiratory 
viruses. 
2. Acute exacerbation of chronic bronchitis (or 
chronic obstructive pulnionary disease, COPII) should 
be treated if episodes of cough and dyspnea occur for 
niore than 3 months a year in at least two consecutive 
years, and if there is evidence for increased sputum 
production during these episodes, and if this sputum 
has increased purulence. 
3. Pneumonia should be treated with antibiotics. 
Pneumonia continues to be a very important cause 
of death. It is the sixth most common cause of death in 
industrialized countries and shows a continuously 
rising rate. Thus, from 1979 to 1994 in the USA, the 
crude death rate due to pneumonia increased by 59% 
from 10.0 to 31.8 deaths per 100,000 population. In 
1992, persons aged > 65 years accounted for 89% of all 
deaths [3], a 44% increase from 1979 (from 145.6 to 
209.1 deaths per 100,000 population). Not only has 
this age group (>65 years) increased in numbers 
significantly in the last 15 years, as a result of the aging 
of the population at large, but pneumonia also becanie 
a niore frequent cause of death [4]. These findings 
underline the importance of pneumonia in the older 
age group and the need for niore effective therapy. 
Following the decision of which patients to treat 
with antibiotics and which patients would profit most 
from supportive care alone, the next question is which 
antibiotic to treat them with. That decision requires a 
knowledge oE: the epidemiology of the disease; risk 
factors; need for hospitalization; risk of dying froni the 
infection; and risk of adverse events caused by the 
administered therapy. In short, it requires a cost-benefit 
analysis. 
From several recent studies of patients with pneu- 
monia who were diagnosed in the community and 
treated at home it appears that in such patients diagnosis 
was made in less than 60%. Streptococcus pneurnoniae was 
the most conmion pathogen diagnosed in 21.3% of 
patients. Haemoplzilus influenxae was isolated in 6.7% of 
cases. Mycoplasrna pneurnoniae was isolated in 1 1 %  of 
cases. Respiratory viruses accounted for a third of all 
diagnosed cases. In several recent publications involving 
patients with community-acquired pneunionia (CAP) 
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who needed hospitalization (2394 patients described in 
six series), etiology was established in 53-7796 (mean 
60.1%). Among these patients, S.  pneumoniae was also 
responsible for 20.8% of the diagnosed infections and 
H. ing’luenzae for 0.51% of the diagnosed cases, similar 
in frequency to &@onella pneurnophila. M .  pneunioniae 
was much less common than in the ambulatory 
patients. Chlamydia pncurnoniae was not looked for 
and therefore not found in these studies, but it is 
undoubtedly a very important pathogen causing 
respiratory infections [5-81. 
Much has been said about the increasing im- 
portance of penicillin-intermediate (MIC 0.1 to 1 .O 
pg/mL) and penicillin-resistant (MIC > 1 .0 pg/mL) S. 
pneurnoniae as an emerging pathogen responsible for 
pulmonary infections. Epidemiologic data are required 
regarding the local susceptibility of these pathogens to 
macrolides and azalides. If found susceptible, roxythro- 
mycin could serve as an appropriate oral alternative. 
H.  injuenzae is also emerging as a problem 
pathogen. Besides the known type B, which may or 
may not be resistant to ampicillin secondary to p- 
lactamase production, other non-typeable ampicillin- 
resistant non-p-lactamase producing strains are also 
isolated with increasing frequency. These strains are 
genetically diverse and have a worldwide distribution. 
They have a lower-level resistance than p-lactamase- 
producing strains, with ampicillin MICs ranging from 
8 to 32 pg/mL. The prevalence of the p-lactamase- 
producing strains also varies between countries, 
depending on whether they belong to type €3 or are not 
typeable. The rate of p-lactamase production in type B 
strains is as high as 31.2%) in Spain, 22.9% in France, 
9.8% in Switzerland, 9.2% in the UK, and 3.9% in 
Germany, but as low as 0% in Italy. The non-type B 
strain had a similar pattern, with a rate as high as 36.2% 
in Spain, 17.4% in Belgium, 14.3% in France, 22% in 
Germany, 8.1% in the UK and 5.3% in Italy. In Spain 
up to 20% of the strains tested were resistant to the 
three antibiotics ampicillin, chloramphenicol and 
tetracycline [9]. 
C. pneumoniae is also emerging as a disease of old 
age. The incidence of the disease may be the mirror 
image of infections with M.  pneurnoniae. While the 
former occurs at a young age, with a peak incidence at 
around 10 years, C. pneurnoniae infections have a peak 
age incidence among people >70 years of age [lo]. 
Serologic studies demonstrate a prevalence of > 50% in 
adults, with epidenlics occurring every 4 to 7 years 
[l 11. This organism has a special ability to survive out 
of the human body for up to 24 h, thereby promoting 
its spread and infectivity. The organism is susceptible to 
attainable concentrations of roxythromycin, other 
niacrolides and tetracyclines. 
The macrolides, including roxythromycin, are 
particularly useful for the management of respiratory 
tract infections. Their spectrum of activity covers most 
of the respiratory pathogens encountered in 
hospitalized patients as well as in patients who can be 
treated at  home [12] (Table 1). Their intracellular 
concentrations, and their concentrations in the 
bronchial mucosa, in lung biopsy specimen, in alveolar 
macrophages, in sputum and in the alveolar lining fluid 
[13] (Table 2), make them excellent candidates for the 
treatment of such infections, both in the community 
and in the hospital. 
Indeed, long before sophisticated pharmacokinetic 
data and recent microbiological susceptibility data of 
‘hard to grow’ pathogens became available, clinical 
experience chose the macrolides as first- and second- 
line therapies in patients with community-acquired 
pneumonias. Guidelines for the initial management of 
adults with CAP issued by the American Thoracic 
Society in 1993 divided patients into four categories, 
with a specific recommendation for therapy in each of 
those groups [14] (Table 3). 
1. In outpatients with pneumonia aged < 60 years 
without co-morbidity (excluding patients at  risk for 
HIV) the suggested therapy was niacrolides or 
tetracyclines. It was recornmended that macrolides be 
prescribed to smokers because of their high rate of H. 
injuenzae infection. 
2. In outpatients with pneumonia and with co- 
morbidity and/or 60 years of age or older, erythro- 
mycin or other niacrolides were recommended as an 
Table 1 MICs of new macrolides against the main bacterial pathogens responsible for CAP 
Minimum inhibitory concentration (mg/L) 
Erythromycin Clarithromycin Roxithromycin Azithroiiiycin 
S. pneumoniae 0.015-0.06 0 .004-0. 0 1 5 0.03-0.20 0.01 5-0.12 
S. pyogenes 0.015-0.06 0.0 1 5-0.0 1 5 0.03-0.25 0.03-0.12 
H. injnerizae 0. 5-8 .0 2.0-8.0 1.0-8.0 0.06-1 .o 
M ,  catarrhalis 0.03 to >8.0 0.034.25 0.12-2.0 0.06-0.15 
R u b i n s t e i n :  M a c r o l i d e s  a s  f i r s t - l i n e  t h e r a p y  in  a d u l t  l o w e r  r e s p i r a t o r y  t r a c t  i n f e c t i o n s  2S25 
Table 2 Antiiillcrobial agent concentrations in human alveolar macrophages (AM) and lining fluid (LF) in  vivo 
Concentration 
Route of AM LF 
Antimicrobial agent Dosage regimen administration ( n 1 g k )  (mg/L) 
-~ 
Azi throniyciri 500 mg  statim Oral 23 1.4 
Roxithroinycin 300 mg twice daily, 5 days Oral 21 2.0 
Jotaniyciri 1 g twice daily, 3 days Intravenous 44 
Cefuroxime axetil 500 mg statim Oral 1.2 0.7 
Aiiioxycilliii 500 nig statim Oral 2.0 2.6 
Clavulanic acid 250 nig statim Oral N r) 1.3 
Spiraiiiycin 500-1000 mg, 1 day Intravenous 17-20 
Cefpirome 1 g statim Intravenous ND" 7.2 
Tenldfloxacin 600 mg  twice daily, 3 days Oral 79.2 26.3 
Statim = immediate dose. 
ND=not detected. 
,'Mostly undztectable, although in two patients levels of 3.1 and 2.2 mg/L were found. 
Table 3 Four major categories of patients with CAP 
(American Thoracic Society, 1993) 
1. Patients < 60 years 
No evidence of co-morbidity 
KX as outpatients 
2. Patieiits: 
With no evidence of co-morbidity 
And/or > 60 years 
K X  as outpatient\ 
Patient\ requiring hospitalization not in ICU 3. 
4 
ICU =intttn,ive carc unit. 
Severe infections requiring ICU cai-c 
alternative therapy to second-generation cephalo- 
sporins, or triniethoprini/sulfaniethoxazole or the 
combination of p-lactarn/p-lactaniase inhibitor. 
3. I n  hospitalized patients with CAP (excluding 
HIV patients) the recomniended therapy was second- 
or third-generation cephalosporin or p-Iactaxdp- 
lactamase inhibitor or a niacrolide. 
4. In severe hospitalized CAP [usually patients 
requiring intensive care unit (ICU) care] the reconi- 
mended therapy was also niacrolide plus third-genera- 
tion cephalosporin with anti-heudomonas activity. 
Thus, according to the US authorities, inacrolides 
are recommended for all f o r m  of CAP either as a first- 
line therapy, or as acceptable alternatives. In Europe, 
the guidelines are not basically different. In France, the 
recommendations for treatment of uncomplicated 
typicai CAP are aiiioxycillin as a first choice or a 
niacrolide. In Germany, the first choice is penicillin, 
and the alternatives are a macrolide or a cephalosporin. 
Penicillin 
Macrolide 
Figure 1 Antibiotic use in Europe in 2056 cases of lower 
respiratory tract infection. From Ortqulst [ 151. 
Bli= p-lactaniase inhibitor. 
In Italy, the first choices are penicillin, anioxycillin, 
ampicillin plus sulbactani, and amoxycillin plus 
clavulanic acid, and the alternative is a niacrolide. In 
Spain, the first choices arc procaine/penicillin and 
ampicillin, and the alternative is a macrolide. In the 
UK, the first choices are aiiioxycillin, ampicillin and 
penicillin, and the alternatives are a macrolide or a 
second-generation cephalosporin. 
Thus, in industrialized countries, macrolides are 
considered agents of first and second choice for the 
therapy of community-acquired pneunionias of all 
grades of severity. These therapeutic recommendations 
are based on  microbiological and epidemiologic 
considerations, pharmacokinetic data, and above all, 
results of clinical studies. Indeed, studies documenting 
the use of the niacrolides in respiratory infections 
in Europe wggest that they are used in about 30% 
of all patients with respiratory tract infections [ 151 
(Figure 1) .  
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